New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩89.5b market cap, or US$60.7m). New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩104.4b market cap, or US$70.9m). Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩2,030, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 49% over the past three years. Ankündigung • Feb 26
HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026 HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South Korea Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩2,160, the stock trades at a trailing P/E ratio of 58.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 45% over the past three years. Board Change • Dec 31
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩77.8b market cap, or US$56.1m). Board Change • Aug 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Feb 22
HLB PANAGENE Co., LTD., Annual General Meeting, Mar 24, 2025 HLB PANAGENE Co., LTD., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South Korea New Risk • Oct 02
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩130.4b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Market cap is less than US$100m (₩130.4b market cap, or US$98.7m). New Risk • Sep 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.9% increase in shares outstanding). New Risk • Jul 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding). Ankündigung • May 16
HLB PANAGENE Co., LTD. announced that it has received KRW 8.92258042 billion in funding On May 14, 2024, HLB PANAGENE Co., LTD. closed the transaction. Ankündigung • Jan 25
HLB PANAGENE Co., LTD. announced that it has received KRW 2 billion in funding from Gencurix Inc. On January 24, 2024, HLB PANAGENE Co., LTD. closed the transaction. Ankündigung • Jan 18
HLB PANAGENE Co., LTD. announced that it expects to receive KRW 2 billion in funding from Gencurix Inc. HLB PANAGENE Co., LTD. announced a private placement to issue Series 7 Bearer-Type Unsecured Private Placement Convertible Bonds for the gross proceeds of up to KRW 2,000,000,000 on January 17, 2024. The transaction will include participation from a new investor, Gencurix Inc. The bonds will be 100% convertible into 500,125 shares at a conversion price of KRW 3,999 in a period starting from January 24, 2025 and ending on December 24, 2026. The maturity date of the bonds is January 24, 2027. The transaction is expected to close on January 24, 2024. The transaction has been approved by the board of directors of the company. New Risk • Aug 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding). New Risk • Jun 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Is New 90 Day High Low • Jan 14
New 90-day high: ₩5,180 The company is up 7.0% from its price of ₩4,840 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 26% over the same period. Is New 90 Day High Low • Dec 01
New 90-day low: ₩4,105 The company is down 14% from its price of ₩4,750 on 02 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. Is New 90 Day High Low • Oct 23
New 90-day low: ₩4,380 The company is down 9.0% from its price of ₩4,795 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. 
